• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Bristol Myers Squibb

    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 Next >
    Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl® (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY IMTX
    Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Data from Phase 2 PILOT Study of Bristol Myers Squibb’s CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Bristol Myers Squibb to Participate in Bernstein’s 38th Annual Strategic Decisions Conference
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    New Two-Year Deucravacitinib Data Reinforce Durable Efficacy and Consistent Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Bristol Myers Squibb to Participate in Bank of America Securities 2022 Healthcare Conference
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Bristol Myers Squibb Reports First Quarter Financial Results for 2022
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Bristol Myers Squibb Foundation Honors Diversity and Health Equity Leader By Naming Diversity in Clinical Trials Training Program After Him; Welcomes Gilead Sciences as Program Supporter
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with...
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Bristol Myers Squibb Announces Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes at Weeks 48 and 84 in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Receiving Mavacamten
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for Reblozyl® (luspatercept-aamt) Supplemental Biologics License Application
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    Bristol Myers Squibb to Demonstrate the Strength of its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific Session
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma
    From Bristol Myers Squibb
    Via Business Wire
    Tickers BMY
    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.